Following the earnings release, Ocugen's stock rose by 4.08% in premarket trading to $0.69. This movement reflects investor optimism about the company's direction and its gene therapy pipeline. With a beta of 4.23, the stock shows significant volatility compared to the broader market. The stock remains within its 52-week range of $0.515 to $2.06, currently trading 67% below its yearly high, suggesting potential upside if upcoming milestones are achieved. Get exclusive access to detailed valuation models and comprehensive analysis through InvestingPro 's extensive research reports, available for over 1,400 US stocks.